LDHA and cancer: Patients with basal-like/triple negative BC (TNBC) expressed increased levels of LDHA and LDHB in serum measurement and tissue microarray analysis, which were significantly associated with shorter survival, poor prognosis, pathological complete response (pCR) to neoadjuvant chemotherapy and cancer relapse, suggesting the potential of LDHA and LDHB as biomarkers for treatment monitoring [86,87].